Renal cell carcinoma, a metabolic disease

Dr. David Meierhofer, Prof. Dr. Alexander Meissner

October 11, 2021

How do chromophobe renal cell carcinoma (chRCC) cells get nutrients despite poorly developed blood vessels within the tumor? To address this question, we used fluorescent-labeled bovine serum albumin (BSA) to track the uptake of a macro-molecule, a process called macropinocytosis. Compared to healthy kidney cells, chRCC cells showed significant enrichment of macropinocytosis, indicating that this kidney cancer can adapt to nutrient poor conditions. This image features chRCC cells, in blue: nuclei, in red: fluorescent-labeled BSA within chRCC cells.

The area of interest of the Meierhofer group lies in the area of renal cell carcinoma (RCC) and its subtypes.
A brand new timsTOF SCP mass spectrometer (Bruker) will be used to study the spatial proteome at or near single-cell resolution. Metabolic differences, epigenetic marks, and post-translational modifications between adjacent healthy kidney tissues and RCC are waiting to be discovered by a doctoral student combining wet lab and computational molecular biology.

For a general description of our research please have a look at the website of the Mass Spectrometry group.

Go to Editor View